Our Company
Key Facts
Leadership
Governance
History
Compliance & Ethics
Diversity & Inclusion
Our Websites
Achievements
Business Information
R&D
R&D Strategy
In the Pipeline
Disease Areas of Focus
Our R&D
Our Science
R&D Highlights
Major R&D Facilities
Clinical Trials
Products
Patient Assistance Programs
Prescribing Information
R&D
Clinical Trials
Counterfeit Drugs
News
Press Releases
Publications
Media Library
Key Facts
Leadership
Financial Reporting
Features
Achievements
Media Contacts
Subscribe to e-mail alerts
Investors
Key Facts
Stock Information
SEC Filings
Financial Reporting
Events & Presentations
Shareholder Services
Investor Contacts
Partnering
Why Partner With Us?
Areas of Interest
Our Process
Our Partners
Partnering News
Partnering Contact
Responsibility
Bristol-Myers Squibb Foundation
Sustainability
Patient Assistance Programs
Building Our Communities
Grants & Giving
Position on Key Issues
Clinical Trials
Combating Counterfeit Drugs
Achievements
Careers
Job Opportunities
Our Culture
Diversity & Inclusion
Developing Our People
University Recruitment
Achievements
Benefits
Manage My Profile
Apply Now
SITE INDEX
|
CONTACT US
|
TERMS
|
PRIVACY
Health Care Professionals
Access
medical information and resources
Clinical Trials
Bristol-Myers Squibb-sponsored
clinical trials
Need Help Paying for Your Bristol-Myers Squibb Medicines?
Learn about our
assistance programs
.
August 20, 2009
Derivative Action Settlement Notice
Our Environmental Stewardship
Bristol-Myers Squibb
Among Greenest
Companies
Ranked 8th among 500
by Newsweek. With nearly all Sustainability 2010 Goals met, we're refocusing on
new horizons.
LATEST NEWS
October 31, 2009
BARACLUDE® (entecavir) Demonstrated Greater Antiviral Efficacy Compared to Adefovir in New Study of Chronic Hepatitis B Patients with Evidence of Decompensated Cirrhosis
October 31, 2009
Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C
October 29, 2009
Bristol-Myers Squibb Donation to Benefit Students at The Pennington School and Beyond
October 26, 2009
Medarex, Inc. Announces Expiration of Offer to Repurchase its 2.25% Convertible Senior Notes due May 15, 2011
Bristol-Myers Squibb